We are live on ! Find out more
CPX

Canaan Partners XI Portfolio holdings

AUM $127M
1-Year Est. Return 217.49%
This Fund
S&P 500
This Quarter Est. Return
-37.27%
1 Year Est. Return
+217.49%
3 Year Est. Return
+1,311.52%
5 Year Est. Return
10 Year Est. Return
AUM
$240M
AUM Growth
-$148M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
6
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 66.64%
2 Technology 33.29%
3 Consumer Discretionary 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DAWN
1
DELISTED
Day One Biopharmaceuticals
DAWN
$95.9M 39.92%
9,663,645
AEVA
2
Aeva Technologies
AEVA
$1.26B
$79.9M 33.29%
3,697,039
TYRA icon
3
Tyra Biosciences
TYRA
$1.91B
$47.2M 19.65%
4,409,991
RLYB icon
4
Rallybio
RLYB
$84.6M
$16.8M 7%
301,214
VECT
5
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$175K 0.07%
37,051
BRDS
6
DELISTED
Bird Global, Inc.
BRDS
$169K 0.07%
2,771

Similar funds

Canaan Partners XI's Q1 2022 Portfolio in Review

As of Q1 2022, Canaan Partners XI held 6 positions worth $240M, down 38% from $388M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2022: portfolio turnover was 0%. Canaan Partners XI opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 64% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Canaan Partners XI's ten largest holdings make up 100% of its $240M portfolio in Q1 2022.
  • Canaan Partners XI opened 0 new positions and closed 0 in Q1 2022.
  • Canaan Partners XI's portfolio value fell 38% quarter-over-quarter to $240M.

Based on Canaan Partners XI's 13F filing for Q1 2022, filed 28 Apr 2022.